From The Editor
-
A Measure Of Improvement Needed
8/1/2023
New and improved ways of measuring disease symptoms and responses to therapy must overcome established forms of measurement used for regulatory approval.
-
More Than A Seat At The Table
7/3/2023
Bringing different perspectives together is important when debating industry policies, but the middle ground can still be allusive.
-
More Transparency, To A Point
6/1/2023
New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?
-
The Growing Appetite For Obesity Drugs
4/3/2023
New obesity drugs with unprecedented efficacy are coming into the market. Can they turn the tide in the global obesity epidemic?
-
Commercialization Or Bust?
3/1/2023
If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?
-
Choosing Your Battles
2/1/2023
Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
-
The Next Big Thing
1/3/2023
Each January, the J.P. Morgan healthcare conference helps to set the biopharma industry agenda for the coming year. What will be the next big thing in 2023?
-
Only The Creative Survive
12/1/2022
Looking through my 2022 coverage areas, and in reading through my colleagues’ outlook articles, what was most compelling to me were not necessarily the specific issues raised, but how leadership approached those issues to create solutions.
-
Channeling, Or Cancelling, Jack Welch
11/1/2022
Although some of Jack Welch’s past leadership practices have come under fire in recent years, it’s safe to say that one of the most successful CEOs in recent history might have some useful ideas and strategy worth remembering.
-
Tiptoeing Toward A Cure For Type 1 Diabetes
10/3/2022
In working on this month’s cover story, which features Imagine Pharma, a preclinical stage biotech based in Pittsburgh, it was hard not to get swept up in the enthusiasm and promise of the company’s autologous cell therapy treatment for Type 1 diabetes (T1D).